| 1 | Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3. 2019;10:437 doi: 10.1021/acsmedchemlett.8b00484 |
| 2 | Dihydroorotate dehydrogenase inhibitors in anti-infective drug research. 2019;183:111681 doi: 10.1016/j.ejmech.2019.111681 |
| 3 | Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target. 2019;26:6053 doi: 10.2174/0929867325666180913095239 |
| 4 | Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders. 2022;55:128448 doi: 10.1016/j.bmcl.2021.128448 |
| 5 | Pictet–Spengler condensations using 4-(2-aminoethyl)coumarins. 2020;44:13415 doi: 10.1039/D0NJ02664F |
| 6 | Applications of Heterocycles in the Design of Drugs and Agricultural Products. 2021;134:185 doi: 10.1016/bs.aihch.2020.12.001 |
| 7 | Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer. 2020;26:56 doi: 10.3390/molecules26010056 |
| 8 | Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. 2021;9:290 doi: 10.3390/biomedicines9030290 |
| 9 | Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable Target. 2020;8:569 doi: 10.3390/biomedicines8120569 |
| 10 | The expression of sex steroid receptors and sex steroid–synthesizing/metabolizing enzymes in metastasized lymph nodes of prostate cancer. 2019;84:124 doi: 10.1016/j.humpath.2018.09.011 |
| 11 | New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold. 2022;237:114366 doi: 10.1016/j.ejmech.2022.114366 |
| 12 | Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. 2019;167:49 doi: 10.1016/j.ejmech.2019.01.054 |
| 13 | Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer. 2021;36:127817 doi: 10.1016/j.bmcl.2021.127817 |
| 14 | Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid. 2018;150:930 doi: 10.1016/j.ejmech.2018.03.040 |
| 15 | Endocrine Disruptors and Prostate Cancer. 2022;23:1216 doi: 10.3390/ijms23031216 |
| 16 |
Computational modeling studies reveal the origin of the binding preference of 3‐(3,4‐di hydroisoquinolin‐2(
1H
)‐ylsulfonyl)benzoic acids for
AKR1C3
over its isoforms
. 2022;31: doi: 10.1002/pro.4499 |
| 17 | Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo–keto reductase 1C3 target affinity. 2019;10:1476 doi: 10.1039/C9MD00201D |
Journal of Cancer Metastasis and Treatment
